



## Novel Oligonucleotide Therapeutics and Their Delivery

Guest Editors:

**Dr. Ted Lakowski**

College of Pharmacy, University of Manitoba, Apotex Centre, 750 McDermot Ave. W., Winnipeg, MB R3E 0T5, Canada

**Dr. Alejandro Martínez-Águila**

R&D Department Avizor Eye Care Solutions, Ocupharm Research Group, Complutense University, 28037 Madrid, Spain

Deadline for manuscript submissions:

**closed (30 November 2022)**

### Message from the Guest Editors

New oligonucleotide therapeutics are becoming increasingly important. Recent approval of parenteral nanoparticle oligonucleotide formulations such as the Pfizer and Moderna COVID RNA vaccines, siRNA therapies such as, givosiran, patisiran, and aptamer therapies like pegaptanib highlight the importance and the increasing success of oligonucleotide delivery. All of these promising oligonucleotide technologies converge on an important requirement: effective drug delivery methods that can get the oligonucleotide drugs into cells and target the drug to the right tissues. Nanoparticle delivery technology has advanced to meet some of these challenges and newer technologies are being developed that have extended half-lives, and target nanoparticles to particular tissues using “smart” materials, and chemical conjugation. This Special Issue covers the latest information on novel oligonucleotide therapeutics and their delivery. We are seeking original contributions and review articles in these areas.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Ernest Mario School of  
Pharmacy, Rutgers, The State  
University of New Jersey, William  
Levine Hall, Room 225C, 160  
Frelinghuysen Road, Piscataway,  
NJ 08854-8020, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma